Isabel Leroux-Roels is a clinical microbiologist and infection control physician at Ghent University Hospital in Belgium. Since 2017 she is also heading the Center for Vaccinology (CEVAC), a vaccine trial center with dedicated immune-monitoring laboratory. Isabel is associate professor at the Department of Diagnostic Sciences of Ghent University. Her research focuses on the clinical evaluation of safety and immunogenicity of novel vaccines, with a specific emphasis on novel vaccine platforms (e.g. mRNA, viral vectors), vaccine adjuvants and vaccines against respiratory viral infections (influenza, RSV, SARS-CoV-2).
Besides many collaborations with pharmaceutical and biotech companies, Isabel and her team are also actively involved in various international consortium projects such as the Larissa project (Rift Valley fever vaccine; CEPI/Horizon 2020), the Indigo project (effective and affordable influenza vaccines; Horizon 2020) and the Baxerna project (Mycobacterium tuberculosis mRNA vaccine; Horizon-RIA). Isabel is also one of the principal investigators of the AReSVi-006 trial, the ongoing phase 3 study evaluating GSK’s adjuvanted RSV preF3 vaccine in older adults.
Isabel Leroux-Roels is a member of the Belgian NITAG (Superior Health Council), she has (co-)authored more than 60 papers in peer-reviewed journals and is frequently invited as a speaker at (inter)national conferences.
